A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dong-Seong Shin, MD, PhD
Gachon University Gil Medical Center
Principal Investigator - Eon-Hye Kim, MD, PhD
CHA Bundang Medical Center
Principal Investigator - Jung-Ryul Kim, MD, PhD
Samsung Medical Center
Study Chair - Yang-Won Min, MD, PhD
Samsung Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gachon University Gil Medical Center
Incheon, South Korea
Recruiting - Cha Bundang Medical Center
Seongnam-si, South Korea
Recruiting - Samsung Medical Center
Seoul, South Korea
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Sept 2020
- Primary completion
- 30 Jun 2023
- Completion
- 31 Dec 2023
- Last update posted
- 9 Nov 2020
- Registered enrollment
- 28
- Registry id
- NCT04494269
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.